

# AstraZeneca & the Life Science ecosystem

**Graniten Symposium May 16, 2024**

Anders Persson, MSc PhD


Head of Ecosystem Strategy & Projects

BioVenture Innovation Unit

AstraZeneca AB



Inspired by our purpose and values, we're transforming the future of healthcare by unlocking the power of what science can do – for people, society and the planet.



## Our purpose

We push the boundaries of science to deliver life-changing medicines

## Our values



We follow the science



We put patients first



We play to win



We do the right thing



We are entrepreneurial



# Delivered on our growth ambition

Total Revenue growth ambition to achieve  
>\$45bn in 2023 set in 2014



Source: Total Revenue Growth ambition as shown in 2014

Culture of science-led innovation unlocked  
a decade of industry-leading growth

Follow the science

Disciplined investment

Focus

Oncology



BioPharmaceuticals



CVRM



R&I



V&I

Rare Disease



# Ambition Zero Carbon

Our flagship sustainability strategy focuses on driving deep decarbonisation across our global business and value chain.

We were one of the first seven companies worldwide to have our Scope 1–3 GHG emissions reduction targets verified under the Science Based Targets initiative's Net-Zero Corporate Standard.

## By 2026...

...we will have reduced our absolute Scope 1 and 2 GHG emissions by 98%.

## By 2030...

...we will reduce absolute Scope 3 GHG emissions by 50% and become carbon negative for all remaining emissions.


## By 2045...

...we will reduce absolute Scope 3 GHG emissions by 90% and remove residual emissions through nature-based solutions to achieve science-based net zero.\*




# Global reach and presence

- ◆ 5 global R&D centres
- ▲ 5 other R&D centres with discovery research labs
- 27 manufacturing sites in 16 countries



## Employees by reporting region



# Collaboration: central to our success

Working closely with partners inside and outside our industry, we're co-creating innovative solutions that address patients' needs.



# AstraZeneca in Sweden

7.6%

of Sweden's  
total export  
of goods  
2022

Stockholm

Södertälje

Gothenburg

Our Nordic Marketing Company, responsible for the marketing of all our products, has its headquarters in Stockholm.

AstraZeneca's largest drug manufacturing centre in the world is situated in Södertälje.

One of AstraZeneca's five global strategic R&D centres sits in Gothenburg.



# Ecosystem Strategic Objectives

1

Create a Sustainable ecosystem and culture supporting innovation and business growth among start-ups, scale-ups and world leading companies

2

Establish the science and technology of tomorrow with platforms of the future evolved through close collaboration with industry

3

Attract competence and talent, while simultaneously experimenting, learning, and scaling at the intersection of Life Science, Data, and Technology.





# Building a strong Life Science ecosystem

## The journey so far



# A unique initiative of Open Innovation within AstraZeneca



- *Established 2015*
- *The sharing economy applied to life science*
- *Scale-up focus*
- *Sector convergence*
- *Non-competitive synergies*
- *Public-Private-Partnership innovation model (governmental and regional funding)*



1

Strengthen the life science ecosystem

2

Support SME growth

3

Attract talents to the region

# Key features and success factors

## Advanced research infrastructure

Unparalleled access to a vibrant R&D site and AstraZeneca's cutting-edge labs and facilities.



## Expertise and mentorship

Unique mentorship opportunities with AstraZeneca's scientists and experts.



## Collaboration opportunities

The hub catalyses opportunities for collaborations with AstraZeneca and the broader community.



## “Dare to Share” community

Connects members to a dynamic network where collaboration and knowledge sharing thrive.



## Portfolio strategy

Sector convergence & non-competitive synergies.



## Proximity

Physical presence. “Innovation is a contact sport”



## No strings attached

AstraZeneca has no rights - not even “rights of first refusal”





## CCRM Nordic

Capital-efficient, collaborative and sustainable ATMP development

**Center for Commercialization of Regenerative Medicine (CCRM) Nordic is a national center for commercial development and production of advanced therapy medicinal products (ATMPs)**

- CCRM Nordic is a not-for-profit organization established to address bottlenecks in the translation and commercialization of ATMPs in Sweden, the Nordics and Europe.
- Public-private partnership in a collaboration between leading actors
- Builds on the successful CCRM business model; a synergy of company creation/scaling, CDMO services & strategic investing.
- Will establish state of the art facilities for process development and production at the Life Science cluster GoCo Health Innovation City in Mölndal.



Supported by:



GU Ventures



CombiGene



# Creating a Health Innovation Ecosystem Together



GoCo Health Innovation City in Gothenburg, Sweden

### **Confidentiality Notice**

This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this file is not permitted and may be unlawful. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK, T: +44(0)203 749 5000, [www.astrazeneca.com](http://www.astrazeneca.com)

